Herpes Zoster

Subscribe to Selected New Research on Herpes Zoster

3867 relevant articles (192 outcomes, 379 trials/studies) found for this Disease

Description: An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)

Also Known As:

Zona; Shingles; Zoster

Relationship Network

Disease Context: Research Results

Virus Diseases: 1311

DNA Virus Infections: 22

Herpesviridae Infections: 344

Herpes Zoster: 3867

Herpes Zoster Ophthalmicus: 90

Herpes Zoster Oticus: 28

Zoster Sine Herpete: 21

Related Diseases

1.	Chickenpox
2.	Infection
3.	Pain (Aches)
4.	Herpes Zoster
5.	Herpes Simplex

Experts

1.	Wutzler, Peter: 4 articles (12/2004 - 01/2002)
2.	Tyring, Stephen: 3 articles (10/2008 - 05/2007)
3.	Arora, Anita: 3 articles (10/2008 - 05/2007)
4.	Schmid, D Scott: 3 articles (03/2008 - 12/2004)
5.	Gershon, Anne A: 3 articles (03/2008 - 12/2004)
6.	Arukwe, Augustine: 3 articles (03/2008 - 06/2002)
7.	Loparev, Vladimir N: 3 articles (03/2008 - 12/2004)
8.	Sauerbrei, Andreas: 3 articles (12/2004 - 01/2002)
9.	Tyring, S: 3 articles (11/2001 - 01/2001)
10.	Mendoza, Natalia: 2 articles (10/2008 - 05/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Herpes Zoster:

1.	Acyclovir (Aciclovir)FDA LinkGeneric 10/15/1989 - "Regarding the treatment of herpes zoster, aciclovir (ACV) is as the most effective and safe drug available" 06/16/1983 - "Acyclovir recipients with disseminated cutaneous zoster had a significantly accelerated rate of clearance of virus from vesicles, as compared with placebo recipients (P = 0.05 by the Breslow test)." 08/29/1988 - "In summary, oral acyclovir at a dosage of 800 mg five times per day for 10 days for treatment of acute herpes zoster is superior to 400 mg five times per day and favorably alters the course of the disease." 06/01/1997 - "BACKGROUND: Oral acyclovir is a costly antiviral agent shown to be effective in the treatment of herpes zoster" 04/01/1989 - "Acyclovir was found to be effective to treat herpes zoster in these patients" Order ALL the reference details at left...
2.	famciclovir (Famvir)FDA LinkGeneric 06/01/1997 - "Famciclovir safe and effective for management of shingles." 06/01/1996 - "Efficacy of famciclovir in the treatment of herpes zoster." 06/01/2002 - "Baseline and follow-up data from 4 samples of immunocompetent patients with herpes zoster who participated in clinical trials of the antiviral agent famciclovir were examined (N = 1778)" 01/01/2001 - "Famciclovir in treatment of acute herpes zoster: results of two post-marketing surveillance studies in Germany." 03/01/1996 - "Two multicenter clinical trials have shown that famciclovir given during the acute zoster phase accelerated healing of cutaneous lesions" Order ALL the reference details at left...
3.	valacyclovir (valaciclovir)FDA LinkGeneric 09/01/2000 - "Current wholesale prices indicate that valacyclovir is the more cost-effective treatment for herpes zoster ($83.90 vs $140.70 per course)." 11/01/1996 - "Valaciclovir is an effective treatment for herpes zoster in immunocompetent adults" 05/01/2007 - "CONCLUSION: Oral valacyclovir 1.5 g bid is safe and effective for the treatment of uncomplicated herpes zoster in immunocompetent patients over 18 years of age" 05/01/2008 - "The objective of this study was to assess the safety and efficacy of an oral dosage of valacyclovir, 1 g TID versus 2 g TID, for the treatment of herpes zoster in immunocompromised patients > or =18 years of age" 05/01/2007 - "OBJECTIVE: To demonstrate the safety and efficacy of oral valacyclovir 1.5 g twice daily (bid) for the treatment of uncomplicated herpes zoster in immunocompetent patients over 18 years of age" Order ALL the reference details at left...
4.	Vidarabine (Vira-A)FDA Link 04/01/1977 - "Adenine arabinoside is most effective against disseminated herpes simplex virus and disseminated herpes zoster" 05/27/1976 - "These studies show that adenine arabinoside is a drug with promise for therapy of systemic herpes zoster in immunocompromised patients" 05/27/1976 - "Editorial: Efficacy of adenine arabinoside in herpes zoster." 10/14/1982 - "We conducted a double-blind, placebo-controlled trial to assess the value of vidarabine therapy for the prevention of complications from herpes zoster in immunocompromised patients" 06/01/1976 - "Eighty-seven immunosuppressed patients (53 with localized and 34 with disseminated herpes zoster) from 10 institutions were enrolled in a controlled therapeutic trial of adenine arabinoside" Order ALL the reference details at left...
5.	Antiviral Agents (Antivirals)IBA 01/01/1997 - "Adopting the proposed recommendations in design and analysis of future trials should facilitate comparison across trials of the efficacy of antiviral agents in the treatment of herpes zoster." 05/01/2007 - "Because it is standard of care to administer antivirals for the treatment of acute herpes zoster, a placebo-controlled trial is not possible, necessitating the use of historical controls" 01/01/1997 - "Based on this review, recommendations for the design and analysis of future trials of antiviral agents in herpes zoster are proposed" 12/01/1995 - "These elements of good study design should be borne in mind in the evaluation of current and future trails of antiviral drugs in herpes zoster." 10/01/2005 - "Do herpes zoster patients receive antivirals" Order ALL the reference details at left...
6.	Immunoglobulins (Immunoglobulin)IBA 02/01/1988 - "In this study, presence of the M42 mAb did not affect the incidence of A23187-induced ARs, whereas the zona-induced ARs that occurred in both corpus and cauda sperm were inhibited fully with M42 immunoglobulin (Ig) G" 09/01/1992 - "Immunoglobulins in the treatment of herpes zoster]" 12/01/1991 - "Zoster immunoglobulin (ZIG) was never given" 01/01/1983 - "VZ specific antibody titers were compared for various immunoglobulin preparations and found to be 30 times higher in zoster immunoglobulins than in normal immunoglobulins." 12/01/1979 - "Zoster immunoglobulin (ZIG)" Order ALL the reference details at left...
7.	brivudine (brivudin)IBA 01/01/2008 - "We report the case of an 8-year-old immunocompetent boy with a painful lumbosacral herpes zoster that was treated with brivudin and achieved rapid and sustained improvement in the absence of muco-cutaneous or pharmacological side effects." 12/15/2004 - "Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster." 06/01/2003 - "Despite some methodological disadvantages common to this type of study, the present survey provides for the first evidence that brivudin treatment during acute herpes zoster favourably affects the incidence of PHN in immunocompetent elderly herpes zoster patients." 01/01/2008 - "Perineal muco-cutaneous herpes zoster treated with brivudin." 11/01/1980 - "Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster." Order ALL the reference details at left...
8.	InterferonsIBA 02/01/1984 - "Interferon seems also effective for herpes zoster" 01/01/1977 - "Since rIn.rCn was effective in stimulating interferon and since toxicity was considered acceptable, a randomized double-blind study was initiated to determine whether rIn.rCn is effective in the treatment of herpes zoster." 08/01/1984 - "For zoster at least, the efficacy of interferon has been documented in controlled studies" 02/01/1984 - "But herpes zoster usually regresses spontaneously within three weeks, therefore, it is not easy to define efficacy of interferon in this disease" 02/01/1984 - "Therefore, we need to examine the effect of interferon on herpes zoster both in placebo controlled and double-blind trials involving patients with immunocompromised diseases." Order ALL the reference details at left...
9.	VaccinesIBA 10/01/1987 - "jacchus infectivity model should prove useful for determining the efficacy of subunit and live recombinant VZV vaccines as well as for the study of zoster." 09/01/2007 - "Periodic exposure (boosts) to vaccines may potentially help prevent the reactivation of herpes zoster and accumulation of susceptibility in these at-risk groups" 09/01/2007 - "After carefully weighing acquisition and administration costs, anticipated uptake and use, direct and indirect health care costs averted, and quality of life issues, plan leadership decided to cover many of the new vaccines (i.e., rotavirus, RSV, and herpes zoster) under a nonstandard vaccination benefit" 09/01/2007 - "At SelectHealth, recently introduced vaccines for rotavirus, respiratory syncytial virus (RSV), herpes zoster, and human papillomavirus (HPV) have required special attention in terms of pharmacy management" 04/01/2007 - "Preventing papillomavirus infectious and herpes zoster: new vaccines]" Order ALL the reference details at left...
10.	Chickenpox Vaccine (Vaccine, Varicella)IBA 08/01/1995 - "To estimate the efficacy of varicella vaccine for protection against herpes zoster in the elderly, we investigated the incidence of herpes zoster in 500 pediatricians and family practitioners with their fifties and sixties, and history of reexposure to VZV in 61 patients with herpes zoster by questionnaires retrospectively" 01/01/2005 - "Further studies are needed to understand secular trends in herpes zoster before and after use of varicella vaccine in the United States and other countries." 01/01/2002 - "However, the best prevention of PHN is the prevention of herpes zoster disease, and the varicella vaccine is an option which over the next few years will be tested in clinical trials" 09/01/2001 - "The goals of ongoing studies in herpes zoster are to develop interventions that will further reduce the symptoms of PHN and/or to eliminate PHN by prophylaxis using the varicella vaccine" 08/01/1997 - "This study was undertaken to determine whether the causative virus was a vaccine-derived or wild-type virus when zoster occurred in healthy children immunized with varicella vaccine (Oka/Biken)" Order ALL the reference details at left...

Therapies and Procedures

1.	Lasers (Laser) 07/01/1993 - "To assess the optimal size of the hole and to evaluate the efficacy of laser drilling in comparison with that of mechanical zona dissection" 06/01/1996 - "These laser zona-drilled (LZD) oocytes with one hole (LZD1) or two holes (LZD2) and the zona-intact controls were inseminated with spermatozoa at standard concentrations of 5x10(4), 5x10(5), 1x10(6) and 2x10(6)/ml. Fertilization was significantly improved at all sperm concentrations in LZD1 and LZD2 oocytes as compared to the controls" 02/01/2005 - "The aim of this prospective and randomized study was to evaluate the efficacy of quarter-laser zona thinning assisted hatching (qLZT-AH) in improving the implantation of embryos in patients with previous implantation failure" 03/01/2004 - "In order to prevent this, the present study used routine injection through an area of zona pellucida in which laser zona thinning had been applied, providing for both a reduced mechanical stress to the oocyte and assisted hatching" 11/01/2003 - "Randomized controlled study of human zona pellucida dissection using the zona infrared laser optical system: evaluation of blastomere damage, embryo development, and subsequent hatching." Order ALL the reference details at left...
2.	Transplants (Transplant) 07/01/2008 - "Seronegativity at time of transplant conferred over 3 times the risk of development of post-transplant zoster (hazard ratio 3.4; P=0.04) compared with seropositivity" 07/01/2008 - "The risk of developing post-transplant zoster increased with increasing age at transplant, with each decade conferring a 1.42-fold (P=0.009) increase in risk of zoster development" 07/01/2008 - "Thirty-seven subjects developed herpes zoster, corresponding to a follow-up time-adjusted incidence of 11.2% at 4 years post transplant" 01/01/2008 - "The cumulative probability of herpes zoster was 5.8% at 1 year, 18.1% at 3 years and 20.2% at 5 years post-transplant" 01/01/2008 - "BACKGROUND: Solid-organ transplant recipients are at high risk for the development of herpes zoster" Order ALL the reference details at left...
3.	Highly Active Antiretroviral Therapy (HAART) 10/01/2005 - "Male-to-male sex as an HIV risk factor (P = 0.02) and being on HAART at a zoster episode (P = 0.03) were protective against complicated zoster" 10/01/2005 - "Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study." 01/01/2008 - "We hypothesized that the incidence of herpes zoster has decreased in this population as a result of highly active antiretroviral therapy and routine varicella zoster virus immunization" 10/01/2005 - "The effects of HIV on the eye, since the advent of highly active antiretroviral therapy, have been less in countries where such treatment is available but even in such situations ophthalmic zoster can occur at higher CD4 cell counts and can still cause problems" 10/01/2005 - "In multivariate regression, being on HAART (odds ratio [OR] = 2.39, 95% confidence interval [CI]: 1.65 to 3.49) and a CD4 count of 50 to 200 cells/mm (OR = 2.69, 95% CI: 1.44 to 5.01) compared with a CD4 count less than 50 cells/mm were associated with an increased risk of zoster" Order ALL the reference details at left...
4.	Aftercare (After-Treatment) 10/01/1995 - "The zona binding ratio for order A improved from 0.2 (range 0 to 0.5) before treatment to 0.5 (range 0.1 to 1.0) after treatment, the corresponding values for order B were 0.2 (range 0 to 1.0) before treatment and 0.3 (range 0.1 to 0.7) after treatment" 10/01/2007 - "Herpes zoster was observed after treatment in 1 patient" 01/01/2006 - "Changes in subcellular localization of the tight junction protein zona occludens 1 (ZO-1) and cytoskeleton protein actin by immunofluorescence were also assessed after treatment of two SMESs in different dilutions" 11/01/1998 - "Cortical granule (CG) exocytosis, zona reaction, nuclear activation, and developmental ability were examined after treatment" 04/01/1992 - "Non-disseminated herpes zoster developed in four patients, but three of the episodes occurred only after treatment was discontinued" Order ALL the reference details at left...
5.	Transplantation (Transplant Recipients) 09/01/2004 - "We have retrospectively assessed the risk of herpes zoster, the risk factors for its occurrence, and its evolution in a population of 209 consecutive liver transplant recipients" 08/01/2003 - "The other 3 patients VZV-seropositive before transplantation suffered from disseminated zoster" 07/04/2002 - "After two patients in whom zoster developed before transplantation were excluded, the respective rates were 13 percent and 30 percent (P=0.02)" 11/01/1999 - "Disseminated zoster occurring simultaneously with cytomegalovirus (CMV) disease in a renal transplant recipient is potentially life threatening" 01/01/1991 - "Clinical signs of zoster were observed in 6% of patients at third and ninth month after transplantation and were serologically confirmed." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Herpes Zoster

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 192 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>